263 related articles for article (PubMed ID: 31424496)
1. Fropofol prevents disease progression in mice with hypertrophic cardiomyopathy.
Huang Y; Lu H; Ren X; Li F; Bu W; Liu W; Dailey WP; Saeki H; Gabrielson K; Abraham R; Eckenhoff R; Gao WD
Cardiovasc Res; 2020 May; 116(6):1175-1185. PubMed ID: 31424496
[TBL] [Abstract][Full Text] [Related]
2. Myofilament mechanical performance is enhanced by R403Q myosin in mouse myocardium independent of sex.
Palmer BM; Wang Y; Teekakirikul P; Hinson JT; Fatkin D; Strouse S; Vanburen P; Seidman CE; Seidman JG; Maughan DW
Am J Physiol Heart Circ Physiol; 2008 Apr; 294(4):H1939-47. PubMed ID: 18281382
[TBL] [Abstract][Full Text] [Related]
3. Fropofol decreases force development in cardiac muscle.
Ren X; Schmidt W; Huang Y; Lu H; Liu W; Bu W; Eckenhoff R; Cammarato A; Gao WD
FASEB J; 2018 Aug; 32(8):4203-4213. PubMed ID: 29522375
[TBL] [Abstract][Full Text] [Related]
4. Blocking cardiac growth in hypertrophic cardiomyopathy induces cardiac dysfunction and decreased survival only in males.
Luckey SW; Mansoori J; Fair K; Antos CL; Olson EN; Leinwand LA
Am J Physiol Heart Circ Physiol; 2007 Feb; 292(2):H838-45. PubMed ID: 17012357
[TBL] [Abstract][Full Text] [Related]
5. Perturbed length-dependent activation in human hypertrophic cardiomyopathy with missense sarcomeric gene mutations.
Sequeira V; Wijnker PJ; Nijenkamp LL; Kuster DW; Najafi A; Witjas-Paalberends ER; Regan JA; Boontje N; Ten Cate FJ; Germans T; Carrier L; Sadayappan S; van Slegtenhorst MA; Zaremba R; Foster DB; Murphy AM; Poggesi C; Dos Remedios C; Stienen GJ; Ho CY; Michels M; van der Velden J
Circ Res; 2013 May; 112(11):1491-505. PubMed ID: 23508784
[TBL] [Abstract][Full Text] [Related]
6. Diltiazem prevents stress-induced contractile deficits in cardiomyocytes, but does not reverse the cardiomyopathy phenotype in Mybpc3-knock-in mice.
Flenner F; Geertz B; Reischmann-Düsener S; Weinberger F; Eschenhagen T; Carrier L; Friedrich FW
J Physiol; 2017 Jun; 595(12):3987-3999. PubMed ID: 28090637
[TBL] [Abstract][Full Text] [Related]
7. Ranolazine Prevents Phenotype Development in a Mouse Model of Hypertrophic Cardiomyopathy.
Coppini R; Mazzoni L; Ferrantini C; Gentile F; Pioner JM; Laurino A; Santini L; Bargelli V; Rotellini M; Bartolucci G; Crocini C; Sacconi L; Tesi C; Belardinelli L; Tardiff J; Mugelli A; Olivotto I; Cerbai E; Poggesi C
Circ Heart Fail; 2017 Mar; 10(3):. PubMed ID: 28255011
[TBL] [Abstract][Full Text] [Related]
8. Altered C10 domain in cardiac myosin binding protein-C results in hypertrophic cardiomyopathy.
Kuster DWD; Lynch TL; Barefield DY; Sivaguru M; Kuffel G; Zilliox MJ; Lee KH; Craig R; Namakkal-Soorappan R; Sadayappan S
Cardiovasc Res; 2019 Dec; 115(14):1986-1997. PubMed ID: 31050699
[TBL] [Abstract][Full Text] [Related]
9. Sexually dimorphic myofilament function and cardiac troponin I phosphospecies distribution in hypertrophic cardiomyopathy mice.
McKee LA; Chen H; Regan JA; Behunin SM; Walker JW; Walker JS; Konhilas JP
Arch Biochem Biophys; 2013 Jul; 535(1):39-48. PubMed ID: 23352598
[TBL] [Abstract][Full Text] [Related]
10. A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice.
Green EM; Wakimoto H; Anderson RL; Evanchik MJ; Gorham JM; Harrison BC; Henze M; Kawas R; Oslob JD; Rodriguez HM; Song Y; Wan W; Leinwand LA; Spudich JA; McDowell RS; Seidman JG; Seidman CE
Science; 2016 Feb; 351(6273):617-21. PubMed ID: 26912705
[TBL] [Abstract][Full Text] [Related]
11. Pathogenesis of Hypertrophic Cardiomyopathy is Mutation Rather Than Disease Specific: A Comparison of the Cardiac Troponin T E163R and R92Q Mouse Models.
Ferrantini C; Coppini R; Pioner JM; Gentile F; Tosi B; Mazzoni L; Scellini B; Piroddi N; Laurino A; Santini L; Spinelli V; Sacconi L; De Tombe P; Moore R; Tardiff J; Mugelli A; Olivotto I; Cerbai E; Tesi C; Poggesi C
J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28735292
[TBL] [Abstract][Full Text] [Related]
12. Hypertrophic cardiomyopathy R403Q mutation in rabbit β-myosin reduces contractile function at the molecular and myofibrillar levels.
Lowey S; Bretton V; Joel PB; Trybus KM; Gulick J; Robbins J; Kalganov A; Cornachione AS; Rassier DE
Proc Natl Acad Sci U S A; 2018 Oct; 115(44):11238-11243. PubMed ID: 30322937
[TBL] [Abstract][Full Text] [Related]
13. Troponin T and beta-myosin mutations have distinct cardiac functional effects in hypertrophic cardiomyopathy patients without hypertrophy.
Revera M; van der Merwe L; Heradien M; Goosen A; Corfield VA; Brink PA; Moolman-Smook JC
Cardiovasc Res; 2008 Mar; 77(4):687-94. PubMed ID: 18029407
[TBL] [Abstract][Full Text] [Related]
14. Enhanced myofilament calcium sensitivity aggravates abnormal calcium handling and diastolic dysfunction in patient-specific induced pluripotent stem cell-derived cardiomyocytes with MYH7 mutation.
Guo G; Wang L; Li X; Fu W; Cao J; Zhang J; Liu Y; Liu M; Wang M; Zhao G; Zhao X; Zhou Y; Niu S; Liu G; Zhang Y; Dong J; Tao H; Zhao X
Cell Calcium; 2024 Jan; 117():102822. PubMed ID: 38101154
[TBL] [Abstract][Full Text] [Related]
15. Inhibiting cardiac myeloperoxidase alleviates the relaxation defect in hypertrophic cardiomyocytes.
Ramachandra CJA; Kp MMJ; Chua J; Hernandez-Resendiz S; Liehn EA; Knöll R; Gan LM; Michaëlsson E; Jonsson MKB; Ryden-Markinhuhta K; Bhat RV; Fritsche-Danielson R; Lin YH; Sadayappan S; Tang HC; Wong P; Shim W; Hausenloy DJ
Cardiovasc Res; 2022 Jan; 118(2):517-530. PubMed ID: 33705529
[TBL] [Abstract][Full Text] [Related]
16. Constitutive phosphorylation of cardiac myosin regulatory light chain prevents development of hypertrophic cardiomyopathy in mice.
Yuan CC; Muthu P; Kazmierczak K; Liang J; Huang W; Irving TC; Kanashiro-Takeuchi RM; Hare JM; Szczesna-Cordary D
Proc Natl Acad Sci U S A; 2015 Jul; 112(30):E4138-46. PubMed ID: 26124132
[TBL] [Abstract][Full Text] [Related]
17. Mavacamten decreases maximal force and Ca
Awinda PO; Watanabe M; Bishaw Y; Huckabee AM; Agonias KB; Kazmierczak K; Szczesna-Cordary D; Tanner BCW
Am J Physiol Heart Circ Physiol; 2021 Feb; 320(2):H881-H890. PubMed ID: 33337957
[TBL] [Abstract][Full Text] [Related]
18. Increased myofilament Ca2+ sensitivity and diastolic dysfunction as early consequences of Mybpc3 mutation in heterozygous knock-in mice.
Fraysse B; Weinberger F; Bardswell SC; Cuello F; Vignier N; Geertz B; Starbatty J; Krämer E; Coirault C; Eschenhagen T; Kentish JC; Avkiran M; Carrier L
J Mol Cell Cardiol; 2012 Jun; 52(6):1299-307. PubMed ID: 22465693
[TBL] [Abstract][Full Text] [Related]
19. Sex-specific cardiac remodeling in early and advanced stages of hypertrophic cardiomyopathy.
Nijenkamp LLAM; Bollen IAE; Niessen HWM; Dos Remedios CG; Michels M; Poggesi C; Ho CY; Kuster DWD; van der Velden J
PLoS One; 2020; 15(5):e0232427. PubMed ID: 32369506
[TBL] [Abstract][Full Text] [Related]
20. Translational investigation of electrophysiology in hypertrophic cardiomyopathy.
Flenner F; Jungen C; Küpker N; Ibel A; Kruse M; Koivumäki JT; Rinas A; Zech ATL; Rhoden A; Wijnker PJM; Lemoine MD; Steenpass A; Girdauskas E; Eschenhagen T; Meyer C; van der Velden J; Patten-Hamel M; Christ T; Carrier L
J Mol Cell Cardiol; 2021 Aug; 157():77-89. PubMed ID: 33957110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
